Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OX40L/OX40 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OX40L / OX40 ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Trimeric stabilization (ECD-Fc design). Sequence Verified. | View OX40L Products |
| Counter-Receptor (OX40) | OX40 (TNFRSF4) ECD-Fc Protein. For binding/blocking assays. HEK293 Expressed. | View OX40 Products |
| Gene Delivery | OX40 / OX40L Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Cell-based assays preserve native conformation. | View OX40 Products |
| Benchmark Ab | Anti-OX40 / Anti-OX40L (Sequence of Amlitelimab / Rocatinlimab). Recombinant positive control for blocking assays. | View OX40L Products |
| Validator | OX40L siRNA Set. For knockdown verification and specificity controls. | View OX40L Products |
| Related Target A | IL-31RA. Synergistic pathway for atopic dermatitis and pruritus. | View IL-31RA Products |
| Related Target B | TSLP. Upstream modulator in Th2 inflammation. | View TSLP Products |
| Pathway Partner (GITR) | GITR / TNFRSF18. Co-stimulatory checkpoint axis for combination studies. | View GITR Products |
| TNFSF Family (CD40L) | CD40L / CD154 / TNFSF5. Related TNF superfamily ligand for selectivity screening. | View CD40L Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trimeric Ligand Conformation | Native trimeric ECD-Fc design with proper cysteine-mediated oligomerization; Theoretical MW verified by SEC-MALS. HEK293 expressed for native glycosylation. |
| Cross-species cyno/mouse eval | Human/Mouse/Cyno OX40L ortholog proteins available with >95% purity; Sequence homology verified. |
| Blocking vs Non-blocking Epitope Mapping | OX40 Receptor Protein included for competitive binding assays; High-affinity pair confirmed by SPR. |
| Cell Surface Expression Validation | Lentivirus transduction system for 293T/CHO cell line construction; Flow cytometry validated expression. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives / Specificity | Validated siRNA included for specificity checks and target knockdown; Extended TNFSF panel (CD40L, GITR, OX40) for selectivity screening. Endotoxin <1 EU/ug. |
Live OX40L/TNFSF4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (OX40L or OX40)
- ➤ Alternative TNFSF4 Trial Search
- ➤ Latest Resistance Research
- ➤ Latest Mechanism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The OX40/OX40L co-stimulatory axis is one of the most actively pursued targets in immuno-oncology and autoimmune disease modulation. Early-generation therapeutics focused primarily on OX40 receptor agonism for oncology, but the industry is pivoting toward OX40L-targeted antagonism to achieve nuanced immune regulation with improved safety profiles. Major players (Sanofi, Amgen/Kyowa Kirin, Bristol Myers Squibb, AstraZeneca) are advancing drugs like Amlitelimab (anti-OX40L) and Rocatinlimab (anti-OX40) for atopic dermatitis, systemic lupus erythematosus (SLE), asthma, and other Th2-driven diseases. Next-wave R&D aims at optimal dosing, prolonged half-life, and bispecific combinations (e.g., OX40L × TSLP, OX40L × IL-31) to address broader autoimmune landscapes without compromising safety.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antagonist (Blocking Ab) | Sanofi, Amgen, BMS | Atopic Dermatitis, SLE, Asthma | Receptor-Ligand Blocking Assay (Need high-purity OX40L trimer + OX40 protein pair) |
| Agonist mAb (historical) | Pfizer, AstraZeneca (MEDI6383) | Solid Tumors (historical/combo) | Receptor Clustering (Need Lentivirus for cell line; rely on trimeric OX40L-Fc) |
| Bispecifics | Various early-stage biotechs | Immunology | Heterodimer Validation (Need cross-reactive Abs against OX40L trimer) |
| Fc-Fusion Agonist (reference) | AstraZeneca/MedImmune (MEDI6383, discontinued) | Solid Tumors (structural reference only) | Receptor Activation Assay (Need trimeric OX40L-Fc with native glycosylation) |
| CAR-T Targeting | Academic/Preclinical | OX40L+ Tumors | Cell Surface Antigen Quantification (Need Lentivirus-transduced stable cell lines) |
Key Assay Considerations & Molecular Differentiation
- Trimeric Conformation: OX40L (TNFSF4) is a TNF superfamily member requiring native trimerization for biological activity. Use SEC-MALS-verified trimeric ECD-Fc proteins for antibody screening to avoid false positives from misfolded monomers.
- Blocking vs Non-blocking: Differentiate functional neutralizing antibodies from non-blocking binders using competitive SPR/ELISA with OX40-Fc as tracer. TarMart provides positive control benchmarks.
- Cross-species Reactivity: Human OX40L shares ~94% identity with cynomolgus and ~65% with mouse. TarMart offers ortholog panels (human/cyno/mouse) to streamline preclinical candidate selection.
- Endotoxin Control: Immune assays require <1 EU/μg. TarMart uses HEK293 expression (low endogenous endotoxin) and provides LAL test certificates.
- Cell-based Validation: Soluble ECD-Fc may not capture all membrane-bound epitopes. TarMart supplies lentivirus for stable cell line construction, enabling flow cytometry validation with native conformation.
Related Target Recommendations
Collaborate across the co-stimulatory axis and TNF superfamily. Recommended cross-sell targets:
- View OX40 Products – Receptor/counter-receptor for blocking and binding assays.
- View GITR Products – Co-stimulatory checkpoint partner for combination studies.
- View CD40L Products – Related TNFSF ligand for selectivity screening.
- View IL-31RA Products – Synergistic Th2 pathway for atopic dermatitis.
- View TSLP Products – Upstream alarmin in dendritic cell activation.